Skip to main content

Table 1 Demographic, clinical, and serologic characteristics of Scleroderma Renal Crisis (SRC) cases and Systemic Sclerosis (SSc) without SRC disease controls

From: Systemic sclerosis medications and risk of scleroderma renal crisis

 SRC (n = 31)SSc without SRC (n = 322)P-value
Race:
 White48 (15/31)57 (158/279)NS
 Black42 (13/31)24 (66/279)0.03
 Other1 (3/31)20 (63/279)NS
 Sex (%female)74 (23/31)84 (271/322)NS
 Age (yrs)53 (40,60)46 (37, 54)0.01
 Time Between SSc and SRC (yrs)3 (1,5)NANA
 SSc Follow Up (yrs)6 (3,8)5 (2,8)NS
 Pulmonary Fibrosis (%)42 (13/31)31 (100/322)NS
 Pulmonary HTN (%)39 (12/31)12 (40/322)< 0.001
 Cardiac Involvement (%)23 (7/31)5 (17/322)0.002
 GI Involvement (%)77 (24/31)82 (265/322)NS
 RNP (%)90 (28/31)97 (313/322)NS
 Digital Ulcers (%)29 (9/31)23 (73/322)NS
 Prior Prednisone (%)65 (20/31)19 (62/322)< 0.001
 Other IST (%)32 (10/31)32 (104/322)NS
 Diffuse39 (12/31)16 (52/322)0.004
 Limited61 (19/31)74 (237/322)NS
 Sine0 (0/31)1 (4/322)NS
 Unknown0 (0/31)9 (29/322)NS
 ANA:83 (25/30)95 (228/242)0.04
 Speckled41 (9/22)33 (73/221)NS
 Nucleolar27 (6/22)41 (90/221)NS
 Homogeneous18 (4/22)16 (36/221)NS
 Centromere4 (1/22)9 (20/221)NS
 Other9 (2/22)1 (2/221)NS
 RNAPOLIII50 (7/14)19 (15/76)0.02
 Centromere5 (1/17)52 (100/192)< 0.001
 SCL-705 (1/17)18 (40/183)NS
 U3-RNP21 (3/14)28 (11/40)NS
 SSA35 (9/26)13 (29/228)0.006
 SSB8 (2/26)4 (9/219)NS
  1. HTN Hypertension, GI Gastrointestinal, RNP Raynaud’s phenomenon, IST Immunosuppression therapy